Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enfusion (ENFN)
NYSE:ENFN
Holding ENFN?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.06Last Year’s EPS
$0.04Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: 17.46%
|Next Earnings Date:Mar 20, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue and client growth, driven by strategic expansions and product innovations. However, challenges remain in the APAC region and with back book growth. The company's overall outlook remains positive, supported by strong market presence and innovative product developments.Company Guidance
During Enfusion's Q3 2024 earnings call, the company reported a robust performance with a 15% year-over-year revenue growth, reaching $51.2 million in Q3, and an adjusted EBITDA of $11.1 million, representing a margin of 21.8%. The company also signed 38 new clients in the quarter, bringing the total client count to 894. Enfusion's Annual Contract Value (ACV) increased to a record $229,000, marking a 5.7% growth. The company highlighted its success in the U.S. launch market, with 8 new launches in Q3 and a total of 31 year-to-date in the Americas. Furthermore, they reported a significant revenue growth of 22% in EMEA and 6% in APAC, despite geopolitical challenges. Enfusion remains on track for its medium-term guidance of a 20% to 22% revenue growth rate from 2025 to 2027, leveraging product enhancements and strategic client wins to drive expansion.Strong Revenue and Client Growth
Enfusion reported a 15% year-over-year revenue growth to $51.2 million in Q3 2024, with adjusted EBITDA totaling $11.1 million and a margin of 21.8%. The company signed 38 new clients, increasing the total client count to 894.
Expansion in Key Markets
Revenue in the Americas grew by 17% year-over-year, and EMEA saw a 22% growth. Enfusion signed notable clients such as Agile Investment Management and Frontier Global Partners, expanding their market share in institutional asset management.
Innovative Product Developments
The Portfolio Workbench tool continued to drive client wins and expand serviceable TAM, contributing to new client acquisitions and enhanced offerings.
Positive Adjusted Gross Margin
Adjusted gross profit increased by 17% year-over-year to $35.2 million, with an adjusted gross margin of 68.8%, showing sequential expansion for the third quarter.
Record ARR Achievement
ARR crossed the $200 million mark for the first time, reaching $202.7 million, representing a 14% year-over-year increase.
---
ENFN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ENFN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $9.05 | $8.72 | -3.65% |
| Aug 06, 2024 | $8.65 | $7.97 | -7.86% |
| May 09, 2024 | $9.77 | $9.26 | -5.22% |
| Mar 12, 2024 | $8.52 | $9.36 | +9.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Enfusion (ENFN) report earnings?
Enfusion (ENFN) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Enfusion (ENFN) earnings time?
Enfusion (ENFN) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ENFN EPS forecast?
ENFN EPS forecast for the fiscal quarter 2024 (Q4) is $0.06.
---